and the gap junctions (GJs) form the intercalated discs (IDs). The molecular distinction between the components of the IDs in the heart is less evident because the protein constituents of the IDs assemble into a junctional area referred to as area composita. 11 Consequently, the molecular effects of the mutant desmosome proteins in AC could extend to various components and functions of the IDs.
Conventionally, IDs are recognized as cell-cell adhesion structures responsible for maintaining the mechanical integrity of the heart. The IDs are also emerging as molecular hubs regulating signaling pathways involved in cell fate determination, differentiation, and proliferation. [12] [13] [14] [15] [16] Notable among the signaling molecules that localize to the IDs is the β-catenin, the effector of the canonical Wnt pathway, 17 which is inactivated on sequential phosphorylation by casein kinase 1 (CK1) at S45 and glycogen synthase kinase 3β (GSK-3β) on residues S33, S37, and T41. 17 Likewise, protein kinase C-α isoform (PKC-α), which requires PKP2 as a scaffold protein at the junction, also localizes to the IDs. 18 Another component of the IDs is neurofibromin 2 (NF2), also known as Merlin (moesin, ezrin, and radixin-like protein), which is an upstream molecule to the Hippo pathway. 14, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Thus, the canonical Wnt and the Hippo pathways are partly regulated at the cell membrane and likely through the IDs.
We postulate that mutations involving the ID proteins not only impair the structural integrity of the area composita but also disrupt signaling pathways that are regulated at the IDs. Accordingly, perturbed molecular changes in the IDs should affect the Hippo and the canonical Wnt signaling pathways, major regulators of cellular differentiation and proliferation. [23] [24] [25] 27, 29 Activation of the Hippo pathway might also be a mechanism for suppression of the canonical Wnt signaling, 26 which is implicated in the pathogenesis of AC. 30 
Methods
The Institutional Review Board at The University of Texas Health Science Center at Houston approved the protocol. The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health and was approved by the Institutional Animal Care and Use Committee.
A detailed Materials and Methods section is provided as Online Data Supplement.
Human Samples
Human heart samples, without identifiers, from 4 patients with pathologically proven AC and from 2 to 4 normal individuals were used.
Mouse Models
Cardiac-restricted heterozygous DSP-deficient (Nkx2.5-Cre:Dsp W/F ) and cardiac-specific truncated JUP (Myh6:Jup) mice have been described previously.
30,31

HL-1 PKP2:shRNA Myocytes Stable Cell Lines
Two independent, stable HL-1 myocyte lines were established using lentiviruses expressing short hairpin RNAs (shRNAs) that target the coding sequence of the Pkp2 gene.
Histology
Oil Red O, Masson trichrome, and immunofluorescence staining were performed as described previously.
30-35
Molecular Biology
Immunoblotting, coimmunoprecipitation, and quantitative polymerase chain reaction were performed per the conventional methods. 31, [33] [34] [35] Generation of recombinant lentiviruses and induction of adipogenesis were performed as described. 31, 35 The HL-1 myocytes were transfected with the SV40 transcriptional enhancer factor domain (TEAD) and TCF7L2 reporter plasmids. The Hippo and the canonical Wnt signaling pathways were assessed by the ratio of Firefly to Renilla luciferase readouts. 36, 37 The list of antibodies, TaqMan probes, and the shRNA sequence is provided in Online Tables I, II , and III, respectively.
Mobility Shift Detection of Phosphorylated Proteins (Phos-tag)
Mn 2+ -Phos-tag SDS-PAGE was prepared per another protocol. 38 The membranes were probed with antibodies that detect both the total and the phosphorylated forms of the intended proteins.
Treatment With PKC Activators PMA and OAG
Subconfluent HL-1 and HL-1 PKP2:shRNA myocytes were treated with either 100 nmol/L of phorbol-12-myristate-13-acetate (PMA) or 50 µmol/L of 1-oleoyl-2-acetyl-sn-glycerol (OAG) for 15 or 30 minutes to activate PKC-α.
Treatment With CK1, GSK-3β, and Proteasome Inhibitors
Subconfluent cells were treated with IC261, an inhibitor of CK1, or 6-bromoindirubin-3′-oxime (BIO), an inhibitor of GSK-3β, or MG132 to block the ubiquitin proteasome system.
RNA Sequencing and Ingenuity Pathway Analysis
DNAse-digested and rRNA-depleted RNAs were sequenced on an Illumina HiSeq instrument using sequencing reagents for a pair-end 100-basepair run. Library was prepared using the Illumina TruSeq RNA library preparation kit. The CASAVA software was used for sequence readout. Sequencing reads were mapped to the mouse reference genome build 9 and analyzed by TopHat. Differentially expressed genes were analyzed using the Cufflink package. The transcript counts were normalized and represented as fragments per kilobase of transcript per million mapped fragments. The data were also analyzed by de novo transcriptome assembly using RNA-Seq by Expectation Maximization software package, and the normalized data were represented as transcript per million. Heat maps were plotted using R (http://www.rstudio.com/), and Volcano plots were graphed using MATLAB and GraphPad Prism software. The threshold for a false discovery rate (q value) was set at 0.05.
Statistics
Differences in the mean±SD of the continuous variables with a normal distribution pattern between the 2 groups were compared by the t test and among multiple groups by the ANOVA, followed by pairwise comparisons. 35 Continuous variables that did not follow normality and the categorical variables were analyzed by the Kruskal-Wallis test or by the χ 2 test.
Results
Molecular Remodeling of IDs in the Human Hearts From Patients With AC
To determine the molecular changes in the ID proteins in AC, we obtained ventricular tissues from the explanted hearts of 4 anonymous patients with the clinical diagnosis and pathological diagnosis of advanced AC who were undergoing heart transplantation. Control hearts were donor hearts that were not used for transplantation. Histological examination of the ventricular tissues showed replacement of the myocytes by fibro-adipocytes in the AC hearts and was normal in the control hearts ( Figure 1A ). Expression levels and localization of selected ID proteins were significantly altered in the AC hearts. Junctional localizations of JUP, PKP2, DSC2, DSG2, and DSP were significantly reduced in the human hearts with AC ( Figure 1A ). In addition, localization of GJA1 (connexin 43), a GJ protein involved in electric conduction and arrhythmogenesis, was also perturbed. Immunoblotting showed marked reductions in the JUP, PKP2, DSC2, DSG2, and DSP, as well as in GJA1 levels in the hearts of patients with AC ( Figure 1B and 1C) . Localization of CDH2 (N-cadherin) to IDs was also reduced. However, a consistent change in CDH2 protein level was not detected ( Figure 1A-1C) .
Activation of the Hippo Pathway in AC
To test the hypothesis that the molecular remodeling of the IDs perturbs signaling pathways regulated at the junction, protein levels and localization of selected components of the Hippo pathway in the human hearts with AC were determined. NF2 and, to a lesser extent, phosphorylated NF2 (pNF2; S518) levels were increased significantly in the human hearts with AC ( Figure 2A and 2B). pNF2 was predominantly localized to the IDs in the normal heart. In contrast, no discernible localization to the IDs was detected in the AC hearts ( Figure 2C ). The total NF2 was diffusely expressed in the myocardium, without a clear localization to IDs in the normal and AC hearts ( Figure 2C ). In conjunction with the increased NF2 levels, levels of phosphorylated Yes-associated protein (pYAP; S127), the downstream cascade target of NF2, were also increased in the human hearts with AC. pYAP was predominantly localized to junctions in the AC hearts ( Figure 2C ). There was no significant change in the phosphorylated WW domain containing transcription regulator 1, pWWTR1, a transducer of the Hippo pathway ( Figure 2A ). Changes in the expression levels and localization of pYAP and pNF2 were more prominent in the epicardial region ( Figure 2D ). To corroborate the findings in the human hearts in the mouse models of AC, the Nkx2. 5 Figure 3A and 3B). In contrast, pNF2 (inactive) was reduced, suggesting an increase in the level of active (nonphosphorylated) NF2. In accord with increased NF2 levels, pYAP and, to a lesser degree, phosphorylated mammalian STE20-like protein kinase 1 (pMST1) levels were also increased in the hearts of the mouse models ( Figure 3A and 3B). Increased levels of the phosphorylated Hippo components were consistent with changes in the levels and localization of the pNF2, pMST1/2, and pYAP, as detected by immunofluorescence staining of myocardial sections ( Figure 3C and 3D). As observed in the human hearts, pNF2 and pYAP were predominantly localized to the cell membrane and prominently in the epicardial regions ( Figure 3D ).
To investigate mechanistic consequences of molecular remodeling of IDs and activation of the Hippo pathway, PKP2, the most common causal gene in AC, 8, 9 was knocked down in the HL-1 myocytes using recombinant lentiviruses expressing 2 independent sets of shRNAs against the Pkp2 gene. Knockdown of PKP2 in the HL-1 myocytes (HL-1 PKP2:shRNA ) was confirmed by quantitative polymerase chain reaction of the Pkp2 mRNA, immunofluorescence, and immunoblotting of the PKP2 protein ( Figure 4A -4C). PKP2 protein was reduced by 66.6±17% (49%-88%) in the HL-1 PKP2:shRNA myocytes ( Figure 2C ).
To identify changes in the transcriptome upon knockdown of the PKP2, whole-transcriptome sequencing (RNA sequencing) was performed. Ingenuity pathway analysis and upstream regulator analysis indicated activation of the Hippo pathway, as shown by reduced mRNA levels of genes positively regulated by the YAP/TEAD (the latter is a transcription factor of the Hippo pathway) in the HL-1 PKP2:shRNA myocytes ( Figure 4D -4G). A list of differentially expressed transcripts is provided in Online Table IV . Reduced transcript levels of the selected YAP-TEAD targets were confirmed by quantitative polymerase chain reaction ( Figure 4H ). To delineate the molecular changes responsible for activation of the Hippo pathway and suppression of gene expression through YAP-TEAD, protein constituents of the Hippo kinase cascade were analyzed by immunoblotting, Phos-tag blot, and immunofluorescence. Expression levels of several molecules of the Hippo pathway were increased markedly in the HL-1 PKP2:shRNA myocytes ( Figure 4I and 4J ). The level of active NF2 was increased in conjunction with increased levels of phosphorylated forms of its downstream kinases pMST1/2, phosphorylated large tumor suppressor kinases 1/2 (pLATS1/2), and pYAP (the latter is transcriptionally inactive effector of the Hippo pathway) ( Figure 4I and 4J). Increased pYAP levels were also confirmed by Phos-tag blotting ( Figure 4K ). To strengthen the evidence January 31, 2014 for activation of NF2, protein levels of pERK44/42 (mitogen activated protein kinase 1/3) and ras-related C3 botulinum toxin substrate 1, which are negatively regulated by active NF2, [39] [40] [41] were determined. pERK44/42 and ras-related C3 botulinum toxin substrate 1 levels were significantly reduced in the HL-1 PKP2:shRNA myocytes ( Figure 4I ). Finally, TEAD transcriptional activity, determined on transfection of the control HL-1 and HL-1 PKP2:shRNA myocytes with a TEAD-luciferase reporter construct, was reduced by 55±16% in the HL-1 PKP2:shRNA myocytes ( Figure 4L ). Collectively, the findings substantiate activation of the Hippo kinase pathway, inactivation of YAP, and suppression of gene expression through TEAD transcription factor in AC.
Inactivation of PKC-α
Active phosphorylated PKC-α (pPKC-α), which inactivates NF2 by phosphorylation, 19, 28 requires PKP2 as a scaffold protein for localization to the junction. 18 pPKC-α was partially localized to the IDs in the normal hearts in a pattern similar to that of PKP2 ( Figure 5A ). In contrast, no discernible localization of pPKC-α (T696) to IDs was detected in the human hearts with AC ( Figure 5A ). Likewise, pPKC-α protein levels were also reduced in the human hearts with AC ( Figure 5B and Online Figure IA) .
Corroborating the findings in the human hearts, pPKC-α was also localized to the IDs in the nontransgenic mouse heart, whereas its localization to the IDs was significantly reduced in the hearts of Nkx2.5-Cre:Dsp W/F and Myh6:Jup mice ( Figure 5C ). Likewise, pPKC-α levels were noticeably reduced in the mouse models of AC as compared with control nontransgenic mice ( Figure 5D and Online Figure IB) .
As observed in the in vivo studies, pPKC-α levels were significantly reduced in the HL-1 PKP2:shRNA myocytes ( Figure 5E ). Likewise, immunofluorescence staining showed localization of the pPKC-α to the membrane, cytosol, as well as the nucleus in the control HL-1 myocytes. In contrast, pPKC-α was almost absent in the membrane in the HL-1 PKP2:shRNA myocytes and was ) and the effector of the Hippo pathway phosphorylated Yes-associated protein (pYAP) in the human hearts with AC (n=4 for each group; *P<0.05). Level of WW domain containing transcription regulator 1 (pTAZ) (a coactivator of YAP) was unchanged. C, Immunofluorescence panels showing localization of pNF2 to the intercalated disc (ID) in the normal hearts but not in the hearts with AC. The Hippo pathway components phosphorylated mammalian STE20-like protein kinase 1 (pMST1) and large tumor suppressor kinase 2 (LATS2) had a diffuse distribution in the human heart. Likewise, pYAP was predominantly localized to cell junctions in the hearts with AC. D, Immunofluorescence panels showing impaired localization of pNF2 to the ID and increased pYAP at the epicardium in the human hearts with AC.
predominantly in the nucleus ( Figure 5F ). To determine the effects of reduced pPKC-α on phosphorylation of NF2, control HL-1 and HL-1 PKP2:shRNA myocytes were treated with 2 different general PKC (and PKD) activators, namely PMA and OAG. Despite treatment with PMA and OAG, membrane localization of pPKC-α remained reduced in the HL-1 PKP2:shRNA myocytes ( Figure 5G and 5H). Treatment with PMA and OAG increased pPKC-α levels in the wild-type HL-1 myocytes but not in HL-1 PKP2:shRNA myocytes ( Figure 5I and 5J and Online Figure IC and ID). In conjunction with the changes in the pPKC-α levels, pNF2 levels were increased in the wild-type HL-1 but not in the HL-1 PKP2:shRNA myocytes ( Figure 5J ).
Suppression of the Canonical Wnt Signaling
Because activation of the Hippo pathway is known to suppress the canonical Wnt signaling, 26 which is implicated in the pathogenesis of AC, 30, 31 changes in the levels and localization of total and pβ-catenin in the human hearts with AC, mouse models, and the HL-1 PKP2:shRNA myocytes were analyzed. Levels of pβ-catenin were significantly increased in the human hearts with AC ( Figure 6A and 6B) , whereas the total β-catenin levels were unchanged ( Figure 6A and 6B). However, localization of the β-catenin was significantly altered, being localized to the IDs in the normal heart ( Figure 6C) but not in the human hearts with AC ( Figure 6C ). As observed in the human hearts with AC, pβ-catenin levels were markedly increased in the myocardial protein extracts from the Nkx2.5-Cre:Dsp W/F and Myh6:Jup mice ( Figure 6D ). Both pβ-catenin and total β-catenin were primarily localized to the cell membrane in the myocardial sections of wild-type, Nkx2.5-Cre:Dsp W/F , and Myh6:Jup mice, both at the midventricular wall ( Figure 6E ) as well as at the epicardium ( Figure 6F) .
To analyze the canonical Wnt signaling, whole-transcriptome data from the HL-1 and HL-1 PKP2:shRNA myocytes, obtained by the unbiased approach of RNA sequencing, were W/F and Myh6:Jup mouse models of AC showing increased neurofibromin 2 (NF2) and reduced phosphorylated NF2 (pNF2) levels and the corresponding increase in the phosphorylated Yes-associated protein (pYAP) level in the heart, as compared with nontransgenic (NTG) mice. B, Quantitative data for total NF2, pNF2 (inactive), and pYAP levels in the mouse models of AC as compared with controls (n=2; *P<0.05; **P<0.002; ***P<0.0001). C, Immunofluorescence panels of mid myocardial sections from Nkx2.5-Cre:DspW/F and Myh6:Jup mice showing localization of pNF2, phosphorylated mammalian STE20-like protein kinase 1 (pMST1), and pYAP in the control and mouse models of AC. As observed in the human hearts with AC, pYAP and pNF2 are predominantly localized to cell membrane. D, Immunofluorescence staining of the epicardial region of the heart in mouse models of AC showing distinct localization of pNF2, pMST1, and pYAP to the cell junction. TUBA1B indicates tubilin alpha 1B. analyzed. Ingenuity pathway analysis suggested suppression of the canonical Wnt signaling in the HL-1 PKP2:shRNA myocytes. Transcript copy number of the selected established canonical Wnt targets was reduced in the HL-1 PKP2:shRNA myocytes ( Figure 7A ). Conversely, mRNA levels of selected genes negatively regulated by the canonical Wnt pathway were increased ( Figure 7B ). The RNA sequencing findings were corroborated by quantitative polymerase chain reaction for a selected number of the well-established canonical Wnt targets ( Figure 7C ). The most marked reduction was in the Ccnd1 mRNA, which was reduced by 99±5% (n=19; P<0.0001). In conjunction with changes in the mRNA levels of Ccnd1, CCND1 protein was also significantly reduced in the HL-1 PKP2:shRNA myocytes ( Figure 7D and 7E) . Moreover, pβ-catenin was significantly increased in the HL-1 PKP2:shRNA myocytes, in accord with the findings in the human hearts with AC and the mouse models ( Figure 7E ). In addition, localization of the β-catenin to cell membrane was significantly reduced in the HL-1 PKP2:shRNA myocytes, whereas pβ-catenin was diffusely distributed ( Figure 7F and 7G) . To determine whether inactivation of β-catenin by phosphorylation was associated with reduced canonical Wnt transcriptional activity, HL-1 and HL-1 PKP2:shRNA myocytes were transfected with a transcription factor 7-like 2 (TCF7L2) reporter construct and luciferase activity was determined. The luciferase activity was reduced by 54±25% (n=9; P=0.0019) in the HL-1 PKP2:shRNA myocytes ( Figure 7H ). In accord with suppressed canonical Wnt signaling, adipogenesis was enhanced in HL-1 PKP2:shRNA myocytes, as detected by Oil Red O and immunofluorescence staining for peroxisome proliferator-activated receptor gamma, an adipogenic transcription factor (Figure 7I-7K) .
Binding of pYAP, pβ-Catenin, and JUP
To determine a molecular link between the Hippo and the canonical Wnt pathways and the IDs, protein extracts from human hearts with AC and controls were analyzed by coimmunoprecipitation. YAP and pβ-catenin as well as YAP and JUP were coimmunoprecipitated in the human heart protein extracts ( Figure 8A ). The corresponding coimmunoprecipitated blots in HL-1 and HL-1 PKP2:shRNA myocytes also corroborated coimmunoprecipitation of YAP and pβ-catenin as well as YAP and JUP ( Figure 8B ). To determine whether increased pβ-catenin in the HL-1 PKP2:shRNA myocytes was affected by inhibition of CK1 or GSK-3β, which sequentially phosphorylate β-catenin for inactivation, HL-1 and HL-1 PKP2:shRNA myocytes were treated with inhibitors of CK1 (IC261) or GSK-3β (BIO). Treatment with IC261 reduced pβ-catenin levels in the control HL-1 cells but did not normalize differentially increased pβ-catenin in the HL-1 PKP2:shRNA myocytes because the pβ-catenin remained significantly elevated in the HL-1 PKP2:shRNA myocytes ( Figure 8C ). Changes in the pβ-catenin correlated with similar changes in pYAP levels, which remained differentially increased in the HL-1 PKP2:shRNA myocytes, as compared with wild-type HL-1 myocytes ( Figure 8C ). Likewise, treatment with BIO did not normalize differentially increased pβ-catenin in the HL-1 PKP2:shRNA myocytes ( Figure 8D ). Finally, because unbound pβ-catenin is subject to degradation by the proteasome system, HL-1 and HL-1 PKP2:shRNA were treated with MG132, an inhibitor of the ubiquitin proteasome system. Treatment with MG132 increased pβ-catenin levels in the control HL-1 and the HL-1 PKP2:shRNA myocytes without normalizing the differentially increased pβ-catenin levels in the HL-1 PKP2:shRNA myocytes ( Figure 8E ).
Rescue of Adipogenesis on Suppression of LATS1/2
To determine the pathogenic role of activation of the Hippo pathway in AC, LATS1 and LATS2, key upstream molecules that inactivate YAP by phosphorylation, were knocked down in the control HL-1 and HL-1 PKP2:shRNA myocytes. Recombinant lentiviruses expressing 4 independent sets of shRNAs were analyzed to identify the most effective shRNA targeting Lats1 and Lats2, independently, followed by pairwise testing against both genes (Online Figure IIA-IID and Figure 9A-9C ). Selected pairs of shRNAs suppressed mRNA levels of Lats1 and Lats2 by 75±10% ( Figure 9A and 9B) . Likewise, LATS1 protein was markedly reduced with combined pairs of shRNAs in the HL-1 as well as in the HL-1 PKP2:shRNA myocytes ( Figure 9C ). Knockdown of LATS1/2 was associated with reduced levels of pYAP, which were more pronounced in the HL-1 PKP2:shRNA myocytes ( Figure 9C ). Similarly, levels of pβ-catenin and β-catenin were reduced on knockdown of LATS1 and LATS2. Simultaneous knockdown of LATS1 and LATS successfully rescued and normalized adipogenesis in the HL-1 PKP2:shRNA myocytes ( Figure 9D-9G) . Accordingly, expression level of peroxisome proliferator-activated receptor gamma, a transcription factor regulating adipogenesis, which was increased in the HL-1 PKP2:shRNA myocytes, was normalized on knockdown of LATS1 and LATS2 in 2 independent cell lines ( Figure 9D) . Similarly, the number of cells expressing peroxisome proliferator-activated receptor gamma in the nucleus was reduced to the baseline level ( Figure 9E and 9F) . Finally, the number of cells that contained fat droplets, as detected by Oil Red O staining, was also normalized (Figure 9E and 9G) .
Discussion
The findings in the human hearts with AC, mouse models, and HL-1 myocytes collectively indicate activation of the Hippo pathway in AC, which contributes to the pathogenesis of adipogenesis in AC. The trigger for the activation of the Hippo pathway is presumed to be the molecular changes at the IDs in human patients with advanced AC. Accordingly, levels of several ID proteins were markedly reduced, a finding that is in accord with the previous data showing reduced junctional localizations of JUP in AC. [42] [43] [44] The findings, in view of monogenic pathogenesis of AC, suggest that the assembly of the IDs requires coordinated interactions between its protein constituents. 45 Impaired ID assembly not only is expected to affect the mechanical integrity of myocyte-myocyte attachment but also instigates a series of signaling events that are regulated at the IDs. Notably, the β-catenin, which also localizes to the IDs, was partially inactivated by phosphorylation at the CK1 and GSK-3β phosphorylation sites. In addition, junctional localization of pPKC-α, which requires PKP2, 18 and its levels were reduced. In conjunction with partial inactivation of pPKC-α, NF2 or Merlin, which is inactivated on phosphorylation by pPKC-α, was activated in AC. 19, 28 Activation of NF2 was associated with cascade phosphorylation of the Hippo kinases, including MST1/2, LATS1/2, and YAP (the latter is the effector of the Hippo pathway, which is inactivated on phosphorylation). Consequently, gene expression through YAP-TEAD was suppressed. Moreover, coprecipitation of YAP, β-catenin, and JUP was associated with increased membrane localization of YAP and β-catenin, which might contribute to suppression of gene expression through the Hippo and the canonical Wnt pathways, respectively. These molecular changes were associated with enhanced adipogenesis in AC models, which was rescued on knockdown of LATS1/2 or expression of active YAP. Collectively, the findings in the human hearts, mouse models, and the HL-1 myocytes indicate activation of the Hippo pathway through the IDs and provide for a novel mechanism for the pathogenesis of enhanced adipogenesis in AC.
The extent of the molecular changes observed in the human hearts with AC is remarkable and seemingly in discord with the monogenic nature of AC, wherein the primary defect is in a single protein. This finding likely reflects the necessity of coordinated stoichiometric assembly of protein constituents of the IDs. 45, 46 In the human AC, a considerable number of the causal mutations result in or are expected to result in haploinsufficiency. 8, 10 The changes are also in accord with the current view on the ID structure in the heart lacking distinct components, as opposed to the epithelial cells, which have distinct substructures. 11 The observed molecular changes also extend beyond proteins that are conventionally known as the desmosome proteins and involve others, such as the GJ protein GJA1. The diversity of the molecular changes, such as impaired GJA1 and SCN5A, a subunit of the sodium channel protein, localization, and function 47, 48 might partially explain the phenotypic complexity of the AC.
IDs, conventionally recognized as the structures responsible for the mechanical integrity of myocyte-myocyte attachment, are emerging as signaling hubs regulating contact-mediated pathways involved in cellular differentiation and proliferation. 16, 17, 25, 26, 49 NF2 (Merlin), an upstream molecule of the Hippo pathway, which localizes to the IDs and is known to interact with β-catenin, PKC-α, and cadherins, 14, [19] [20] [21] [22] [23] [24] 50 is activated in AC. Reduced PKP2 resulting in impaired junctional localization of pPKC-α 18 provide a potential instigator for activation of NF2 in AC. Activation of NF2 was corroborated at multiple levels, albeit indirectly, by showing increased levels of the nonphosphorylated NF2, increased levels of its downstream target pMST1/2, and reduced levels of pERK1/2 and ras-related C3 botulinum toxin substrate 1, which are negatively regulated by the active NF2. 21, 39 Collectively, the findings point to activation of NF2 as a link between the IDs and downstream molecules of the Hippo pathway. Nevertheless, the Hippo pathway in the mammals is not fully understood and the pathway seems to be much more complex than the initially envisioned linear cascade (Online Figure III) . Alternative upstream proteins either directly or indirectly might link impaired assembly of the IDs to activation of the Hippo kinases in AC. Notably, the WW domain protein KIBRA in D. Melanogaster is upstream of NF2 and, along with Angiomotin, coregulates the Hippo pathway. 51 In addition, salvador homolog 1, a coactivator of the Hippo pathway, was recently shown to localize to cell membranes. 50 The Hippo pathway might also be activated through mechanisms other than those directly regulated at the IDs, such as disruption of the actin cytoskeleton. 50, 52 Consistent with this notion, the HL-1 PKP2:shRNA myocytes were smaller, differed in gross morphology, and had perturbed filamentous actin organization (Online Figure V) . The role of these changes in inactivation of the Hippo pathway was not characterized in the present study. Finally, the Hippo pathway molecules are typically tumor suppressor multifunctional proteins with diverse phenotypic effects. 20 Thus, it would not be surprising if alternative and complementary mechanisms activate the Hippo pathway in AC.
The pathogenic role of activation of the Hippo pathway in adipogenesis might be related to its suppressive effects on the canonical Wnt signaling. YAP binds to β-catenin and JUP ( Figure 8A ), which might result in membrane localization of pYAP, as observed in the human AC. These molecular interactions could sequester β-catenin and YAP and suppress the canonical Wnt and Hippo pathways, shifting the cell fate toward an adipogenic lineage. 53 Activation of the Hippo pathway and inactivation of YAP are also implicated in the PKA-induced adipogenesis. 50 YAP has been shown to inactivate phosphatase and tensin homolog, which is known to block the insulin-like growth factor 1/mechanistic target of rapamycin 1 pathway and adipogenesis. 54, 55 The cardiac cell type targeted by the Hippo pathway for differentiation to adipocytes in AC remains to be identified. Moreover, the Hippo pathway has been shown to regulate cardiac myocyte size and proliferation. 26, [56] [57] [58] It is intriguing to postulate that activation of the Hippo pathway might also be a mechanism for myocyte atrophy, which are typically observed in the human AC. 59 Finally, subtle differences in the pNF2 (inactive) level and membrane localization of pβ-catenin between the human heart tissues with AC and the cardiac tissues from the mouse models were noted, which might reflect differences among the species, tissue preparations (formalin-fixed human tissues versus fresh-frozen mouse heart tissues), or the affinity of the antibodies for the mouse and human proteins.
To determine whether activation of the Hippo pathway and inactivation of the YAP contribute to other features of AC, such as cardiac dysfunction or the predominant involvement of the right ventricle, in vivo rescue experiments are required, but they are currently challenging, partly because of the inadequately defined Hippo pathway in the mammalian heart. Genetic manipulation of NF2 is likely to result in a compounded phenotype because of the functional diversity of NF2. 20, 21 Conditional knockout of Salv (salvador homolog 1) has been used to suppress the Hippo pathway. 26 Salvador homolog 1 is a coactivator of the pathway, and its deletion is not expected to suppress the Hippo pathway activated through NF2, as observed in the present studies. Conditional deletion of both Lats1 and Lats2 would be required to inactivate the Hippo pathway and activate YAP. However, this is currently not feasible. Finally, cell-specific expression of an active form of YAP in vivo, as in the in vitro studies, might provide an opportunity to discern the phenotypic effects of inactivation of YAP from those imparted on activation of the upstream Hippo kinases in the pathogenesis of AC.
In conclusion, molecular remodeling of the IDs observed in the human hearts with AC activates NF2 (Merlin), which results in cascade phosphorylation of the Hippo kinases, inactivation of YAP, and enhanced adipogenesis (Online Figure  IV) . The findings corroborated in the human hearts, mouse models, and HL-1 myocytes indicate activation of the Hippo pathway as a novel mechanism in the pathogenesis of AC.
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